A phase i and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3434-3440

  Bekaii Saab, Tanios S ^a,b   Liu, Jing ^c   Chan, Kenneth K ^a,c   Balcerzak, Stanley P ^a   Ivy, Percy S ^d   Grever, Michael R ^a   Kraut, Eric H ^a,c  

^a Division of Hematology and Oncology   (United States)

^b Department of Pharmacology ^*

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; TREATMENT RESPONSE; VOMITING; AREA UNDER THE CURVE; DRUG ADMINISTRATION; HISTORY; MAXIMUM TOLERATED DOSE; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTORY, 17TH CENTURY; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL;

EID: 50349086687     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4903     Document Type: Article

References (39)

1. Raymond E, Faivre S, Woynarowski JM, et al. Oxali-platin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
2. Rixe 0, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-65.
3. Fukuda M, OheY, Kanzawa F, et al. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer sublines resistant to cisplatin. Anticancer Res 1995;15:393-8.
4. Christian MC. The current status of new platinum analogs. Semin Oncol 1992;19:720-33.
5. Zori Comba A, Blajman C, Richardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001;37:1006-13.
6. Pendyala L, Kidani G, Perez R. Cytotoxicity, cellular accumulation, and DNA binding of oxaliplatin isomers. Cancer Lett1995;97:177-89.
7. Scheef ED, Briggs JM, Howell SB. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 1999;56:633-43.
8. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-71.
9. Rowinsky EK, Donehower RC. Paclitaxel. N Engl J Med 1996;332:1004-14.
10. Gu J, Yamamoto H, Lu X, et al. Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion 2006;74:19-27.
11. Grothey A, Oxaliplatin safety profile: neurotoxicity. Semin Oncol 2003;30:5-13.
12. Faivre S, Lechevalier T, Monnerat C, et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced nonsmall cell lung cancer. Ann Oncol 2002;13:1481-9.
13. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antineoplastic agent. J Natl Cancer lnst 1990;82:1247-59.
14. Gallardo-Rincon D, Perez-Landeros L, Oñate-Ocaña LF, et al. Long-term results of paclitaxel in FIGO stage III ovarian carcinoma. Anticancer Drugs 2003;14:347-52.
15. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347-53.
16. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69.
17. Rougier P, Lepere C. Metastatic colorectal cancer: first- and second-line treatment in 2005. Semin Oncol 2005;32:15-20.
18. Louafi S, Mansourbakht T, Bonyhay L, Taieb J. Oxaliplatin in gastro-intestinal tract cancer except colorectal cancer. Bull Cancer 2006;93 Suppl 1:S23-33.
19. Viens P, Petit T, Yovine A, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinumsensitive recurrent advanced ovarian cancer patients. Ann Oncol 2006;17:429-36.
20. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 2005;131:585-90.
21. De Giorgi U, Rosti G, Papiani G, et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol 2004;27:457-60.
22. Winegarden JD, Mauer AM, Otterson GA, et al. University of Chicago Phase II Network; Ohio State University. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004;15:915-20.
23. Delaloge S, Laadem A, Taamma A, et al. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol 2000;23:569-74.
24. WHO. Handbook for reporting results of cancer treatment. Geneva (Switzerland): Offset Publication; 1979.
25. Liu J, Kraut E, Bender J, et al. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol 2002;49:367-74.
26. Schuette W, Blankenburg T, Guschall W, et al. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 2006;7:338-43.
27. Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003;21:2665-72.
28. Aarons L Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 2006;32:669-70.
29. Santini D, Graziano F, Catalano V, et al. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer 2006;6:125.
30. Lordick F, Lorenzen S, Stollfuss J, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005;93:190-4.
31. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997;61:275-91.
32. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25[Suppl 5]:13-22.
33. Luo FR, Wyrick SD, Chaney SG. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 1999;49:19-28.
34. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carbo-platin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3553-44.
35. Veal GJ, English MW, Grundy RG, et al. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemother Pharmacol 2004;54:295-300.
36. Joerger M, Huitema ADR, Richel DJ, et al. Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: a study by the EROTC-PAMM-NDDG. Br J Clin Pharmacol 2006;63:505.
37. Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat. Cancer Chemother Pharmacol 2002;50:445-53.
38. Tanaka R, Ariyarna H, Qin B, et al. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 2005;55:595-601.
39. Jamieson SM, Liu J, Hsu T, Baguley BC. McKeage MJ Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity Br J Cancer 2003;88:1942-7.